{"id":2826,"date":"2021-11-30T10:05:57","date_gmt":"2021-11-30T09:05:57","guid":{"rendered":"https:\/\/wp.idlbiotech.com\/?page_id=2826"},"modified":"2025-05-27T10:57:01","modified_gmt":"2025-05-27T08:57:01","slug":"bolagsordning","status":"publish","type":"page","link":"https:\/\/idldiagnostics.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/","title":{"rendered":"Bolagsordning"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;88f366a5-bf49-48d9-a338-ab22706b73e7&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||0px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||||false|false&#8221; custom_padding_tablet=&#8221;10px||||false|false&#8221; custom_padding_phone=&#8221;0px||||false|false&#8221; custom_padding_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][dipi_breadcrumbs _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; max_width=&#8221;800px&#8221; global_colors_info=&#8221;{}&#8221;][\/dipi_breadcrumbs][et_pb_divider color=&#8221;#EEEEEE&#8221; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; max_width=&#8221;800px&#8221; min_height=&#8221;1px&#8221; height=&#8221;20px&#8221; custom_margin=&#8221;||3px|||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;8738c908-7375-4c6c-99a7-9f91f8a3c099&#8243; header_font_size=&#8221;56px&#8221; max_width=&#8221;800px&#8221; custom_margin=&#8221;||17px|||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h6>Bolagsordning.<\/h6>\n<h1>Bolagsordning.<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;e9afc0e7-c9bf-4a12-be49-63ddba231101&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; max_width=&#8221;800px&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h2>Org. No. 556596-6107<\/h2>\n<h2>Antaget vid \u00e5rsst\u00e4mman den 15 maj 2025.<\/h2>\n<p><strong>\u00a7 1 F\u00f6retagsnamn<\/strong><br \/>Bolagets f\u00f6retagsnamn \u00e4r IDL Diagnostics AB (publ).<\/p>\n<p><strong>\u00a7 2 Styrelsens s\u00e4te<\/strong><br \/>Styrelsen skall ha sitt s\u00e4te i Stockholms kommun.<\/p>\n<p><strong>\u00a7 3 Verksamhet<br \/><\/strong>Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedrivs forsknings-, utvecklings- och tillverkningsarbete samt handel och f\u00f6rs\u00e4ljning av produkter och tj\u00e4nster inom omr\u00e5dena cellbiologi, medicinteknik och diagnostik j\u00e4mte med detta f\u00f6renlig verksamhet.<\/p>\n<p><strong>\u00a7 4 Aktiekapital<\/strong><br \/>Aktiekapitalet ska uppg\u00e5 till l\u00e4gst 22 500 000 kronor och h\u00f6gst 90 000 000 kronor.<\/p>\n<p><strong>\u00a7 5 Antal aktier<br \/><\/strong>Antalet aktier ska uppg\u00e5 till l\u00e4gst 225 000 000 och h\u00f6gst 900 000 000.<\/p>\n<p><strong>\u00a7 6 R\u00e4kenskaps\u00e5r<br \/><\/strong>Bolagets r\u00e4kenskaps\u00e5r skall vara kalender\u00e5r.<\/p>\n<p><strong>\u00a7 7 Styrelsen<\/strong><br \/>Styrelsen skall best\u00e5 av l\u00e4gst tre och h\u00f6gst \u00e5tta ledam\u00f6ter med h\u00f6gst tre suppleanter. Ledam\u00f6terna och suppleanterna v\u00e4ljs \u00e5rligen p\u00e5 \u00e5rsst\u00e4mma f\u00f6r tiden intill slutet av n\u00e4sta \u00e5rsst\u00e4mma.<\/p>\n<p><strong>\u00a7 8 Revisor<br \/><\/strong>F\u00f6r granskning av bolagets \u00e5rsredovisning j\u00e4mte r\u00e4kenskaperna samt styrelsens och verkst\u00e4llande direkt\u00f6rens f\u00f6rvaltning ska en eller tv\u00e5 revisorer utses p\u00e5 st\u00e4mman. Till revisor kan \u00e4ven utses ett registrerat revisionsbolag.<\/p>\n<p><strong>\u00a7 9 \u00c5rsst\u00e4mma<\/strong><br \/>P\u00e5 \u00e5rsst\u00e4mma ska f\u00f6ljande \u00e4renden f\u00f6rekomma.<\/p>\n<p style=\"padding-left: 40px;\">1. Val av ordf\u00f6rande vid st\u00e4mman<br \/>2. Uppr\u00e4ttande och godk\u00e4nnande av r\u00f6stl\u00e4ngd<br \/>3. Val av en eller tv\u00e5 justeringspersoner<br \/>4. Pr\u00f6vning om st\u00e4mman blivit beh\u00f6rigen sammankallad<br \/>5. Godk\u00e4nnande av dagordningen<br \/>6. Framl\u00e4ggande av \u00e5rsredovisning och revisionsber\u00e4ttelse samt, i f\u00f6rekommande fall, koncernredovisning och koncernrevisionsber\u00e4ttelse<br \/>7. Beslut om:<\/p>\n<p style=\"padding-left: 80px;\">a. fastst\u00e4llelse av resultatr\u00e4kning och balansr\u00e4kning samt, i f\u00f6rekommande fall, koncernresultatr\u00e4kning och koncernbalansr\u00e4kning<\/p>\n<p style=\"padding-left: 80px;\">b. dispositioner betr\u00e4ffande bolagets vinst eller f\u00f6rlust enligt den fastst\u00e4llda balansr\u00e4kningen; och<\/p>\n<p style=\"padding-left: 80px;\">c. ansvarsfrihet \u00e5t styrelseledam\u00f6ter och verkst\u00e4llande direkt\u00f6ren<\/p>\n<p style=\"padding-left: 40px;\">8. Fastst\u00e4llande av arvoden \u00e5t styrelse och revisorn\/revisorerna<br \/>9. Val till styrelsen samt av revisor\/er<br \/>10. Annat \u00e4rende, som ankommer p\u00e5 st\u00e4mman enligt aktiebolagslagen (2005:551) eller bolagsordningen.<\/p>\n<p style=\"padding-left: 40px;\"><strong><\/strong><\/p>\n<p><strong>\u00a7 10 Anm\u00e4lan till st\u00e4mma<br \/><\/strong>En aktie\u00e4gare f\u00e5r delta i bolagsst\u00e4mma endast om aktie\u00e4garen anm\u00e4ler detta till bolaget senast den dag som anges i kallelsen till st\u00e4mman. Sistn\u00e4mnda dag f\u00e5r inte vara s\u00f6ndag, annan allm\u00e4n helgdag, l\u00f6rdag, midsommarafton, julafton eller ny\u00e5rsafton och inte infalla tidigare \u00e4n femte vardagen f\u00f6re st\u00e4mman.<\/p>\n<p>En aktie\u00e4gare f\u00e5r ha med sig bitr\u00e4den vid bolagsst\u00e4mman endast om aktie\u00e4garen anm\u00e4ler antalet bitr\u00e4den (h\u00f6gst tv\u00e5) till bolaget p\u00e5 det s\u00e4tt som anges i f\u00f6reg\u00e5ende stycke.<\/p>\n<p><strong>\u00a711 Kallelse<\/strong><br \/>Kallelse till bolagsst\u00e4mma skall ske genom annonsering i Post- och Inrikes Tidningar och genom att kallelsen h\u00e5lls tillg\u00e4nglig p\u00e5 bolagets webbplats. Samtidigt som kallelse sker skall bolaget genom annonsering i Dagens Industri upplysa om att kallelse har skett.<\/p>\n<p><strong>\u00a7 12 Insamling av fullmakter och postr\u00f6stning<br \/><\/strong>Styrelsen f\u00e5r samla in fullmakter enligt det f\u00f6rfarande som anges i 7 kap. 4 \u00a7 andra stycket aktiebolagslagen (2005:551).<\/p>\n<p>Styrelsen f\u00e5r inf\u00f6r en bolagsst\u00e4mma besluta att aktie\u00e4garna ska kunna ut\u00f6va sin r\u00f6str\u00e4tt per post f\u00f6re bolagsst\u00e4mman. Postr\u00f6stning skall om styrelsen s\u00e5 beslutar kunna ske med elektroniska medel.<\/p>\n<p><strong>\u00a7 13 Utomst\u00e5endes n\u00e4rvaro vid bolagsst\u00e4mma<br \/><\/strong>Styrelsen f\u00e5r besluta att den som inte \u00e4r aktie\u00e4gare i bolaget ska, p\u00e5 de villkor som styrelsen best\u00e4mmer, ha r\u00e4tt att n\u00e4rvara eller p\u00e5 annat s\u00e4tt f\u00f6lja f\u00f6rhandlingarna vid en bolagsst\u00e4mma.<\/p>\n<p><strong>\u00a7 14 Avst\u00e4mningsf\u00f6rbeh\u00e5ll<br \/><\/strong>Bolagets aktier skall vara registrerade i ett avst\u00e4mningsregister enligt lagen (1998:1479) om v\u00e4rdepapperscentraler och kontof\u00f6ring av finansiella instrument.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_module=&#8221;3466&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_menu menu_id=&#8221;29&#8243; disabled_on=&#8221;on|on|off&#8221; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#F8F8F8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_menu][et_pb_sidebar area=&#8221;et_pb_widget_area_2&#8243; disabled_on=&#8221;off|off|on&#8221; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;2efbbc8f-7ecb-4fe3-9956-d83a8a0e7a74&#8243; background_color=&#8221;#F8F8F8&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_sidebar][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; custom_padding_last_edited=&#8221;on|tablet&#8221; _builder_version=&#8221;4.9.4&#8243; _module_preset=&#8221;default&#8221; custom_margin_tablet=&#8221;||||false|false&#8221; custom_margin_phone=&#8221;&#8221; custom_margin_last_edited=&#8221;on|tablet&#8221; custom_padding_tablet=&#8221;||0px||false|false&#8221; custom_padding_phone=&#8221;&#8221; global_module=&#8221;2177&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h6>Om oss<\/h6>\n<h3>Vi bist\u00e5r med kunskap till beslutsfattare<\/h3>\n<p>AroCell \u00e4r ett svenskt diagnostikf\u00f6retag med visionen att f\u00f6rb\u00e4ttra \u00f6vervakningen av onkologiska och bakteriella sjukdomar. Vi har ett brett produktutbud av IVD-tester som levererar v\u00e4rdefull klinisk information f\u00f6r uppt\u00e4ckt av sjukdomar.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/idldiagnostics.com\/sv\/om-arocell\/&#8221; button_text=&#8221;L\u00e4s mer om oss&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2022\/10\/MG_7941-800.jpg&#8221; title_text=&#8221;MG_7941-600&#8243; src_tablet=&#8221;&#8221; src_phone=&#8221;https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2023\/08\/MG_7941-600.jpg&#8221; src_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p><div class=\"et_pb_module dipi_breadcrumbs dipi_breadcrumbs_0\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module_inner\">\n\t\t\t\t\t<div class=\"dipi-breadcrumbs dipi-bc-left\">\n                <ul >\n                    \n                                                        <li  class=\"dipi-breadcrumb-item dipi-breadcrumb-home\">\n\n                                                    <a  href=\"https:\/\/idldiagnostics.com\/sv\">\n                                <span  content=\"Home\">\n                                                                        IDL Diagnostics                                <\/span>\n                            <\/a>\n\n                                                <meta itemprop=\"position\" content=\"1\"\/>                    <\/li>\n\n                    <li class=\"dipi-breadcrumb-separator\">\n                    <span class=\"et-pb-icon dipi-separator-icon\">&#x35;<\/span>\n                <\/li>                            \n                <\/ul>\n            <\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>Bolagsordning. Bolagsordning.Org. No. 556596-6107 Antaget vid \u00e5rsst\u00e4mman den 15 maj 2025. \u00a7 1 F\u00f6retagsnamnBolagets f\u00f6retagsnamn \u00e4r IDL Diagnostics AB (publ). \u00a7 2 Styrelsens s\u00e4teStyrelsen skall ha [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3954,"parent":2253,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<!-- wp:divi\/placeholder \/-->","_et_gb_content_width":"","footnotes":""},"dipi_cpt_category":[],"class_list":["post-2826","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bolagsordning - IDL Diagnostics<\/title>\n<meta name=\"description\" content=\"Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bolagsordning - IDL Diagnostics\" \/>\n<meta property=\"og:description\" content=\"Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt\" \/>\n<meta property=\"og:url\" content=\"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/\" \/>\n<meta property=\"og:site_name\" content=\"IDL Diagnostics\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/arocell\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T08:57:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/arocell.com\/sv\/wp-content\/uploads\/2022\/09\/AroCell_logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/\",\"url\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/\",\"name\":\"Bolagsordning - IDL Diagnostics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/idldiagnostics.com\\\/sv\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/AroCell_logo.jpg\",\"datePublished\":\"2021-11-30T09:05:57+00:00\",\"dateModified\":\"2025-05-27T08:57:01+00:00\",\"description\":\"Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/#primaryimage\",\"url\":\"https:\\\/\\\/idldiagnostics.com\\\/sv\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/AroCell_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/idldiagnostics.com\\\/sv\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/AroCell_logo.jpg\",\"width\":300,\"height\":420},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/bolagsordning\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/idldiagnostics.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investerare\",\"item\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"F\u00f6retagsstyrning\",\"item\":\"https:\\\/\\\/arocell.com\\\/sv\\\/investerare\\\/foretagsstyrning\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Bolagsordning\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/arocell.com\\\/sv\\\/\",\"name\":\"IDL Diagnostics\",\"description\":\"Saving lives with diagnostics\",\"publisher\":{\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/arocell.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/#organization\",\"name\":\"IDL Diagnostics\",\"url\":\"https:\\\/\\\/arocell.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/idldiagnostics.com\\\/sv\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/AroCell_logo.png\",\"contentUrl\":\"https:\\\/\\\/idldiagnostics.com\\\/sv\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/AroCell_logo.png\",\"width\":1713,\"height\":570,\"caption\":\"IDL Diagnostics\"},\"image\":{\"@id\":\"https:\\\/\\\/arocell.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/arocell\",\"https:\\\/\\\/linkedin.com\\\/company\\\/arocell\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bolagsordning - IDL Diagnostics","description":"Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/","og_locale":"sv_SE","og_type":"article","og_title":"Bolagsordning - IDL Diagnostics","og_description":"Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt","og_url":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/","og_site_name":"IDL Diagnostics","article_publisher":"https:\/\/www.facebook.com\/arocell","article_modified_time":"2025-05-27T08:57:01+00:00","og_image":[{"width":300,"height":420,"url":"https:\/\/arocell.com\/sv\/wp-content\/uploads\/2022\/09\/AroCell_logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/","url":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/","name":"Bolagsordning - IDL Diagnostics","isPartOf":{"@id":"https:\/\/arocell.com\/sv\/#website"},"primaryImageOfPage":{"@id":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/#primaryimage"},"image":{"@id":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/#primaryimage"},"thumbnailUrl":"https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2022\/09\/AroCell_logo.jpg","datePublished":"2021-11-30T09:05:57+00:00","dateModified":"2025-05-27T08:57:01+00:00","description":"Bolaget ska direkt eller indirekt genom dotterbolag eller andra intressebolag bedriva forsknings-, utvecklings- och tillverkningsarbete samt","breadcrumb":{"@id":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/"]}]},{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/#primaryimage","url":"https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2022\/09\/AroCell_logo.jpg","contentUrl":"https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2022\/09\/AroCell_logo.jpg","width":300,"height":420},{"@type":"BreadcrumbList","@id":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/bolagsordning\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/idldiagnostics.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Investerare","item":"https:\/\/arocell.com\/sv\/investerare\/"},{"@type":"ListItem","position":3,"name":"F\u00f6retagsstyrning","item":"https:\/\/arocell.com\/sv\/investerare\/foretagsstyrning\/"},{"@type":"ListItem","position":4,"name":"Bolagsordning"}]},{"@type":"WebSite","@id":"https:\/\/arocell.com\/sv\/#website","url":"https:\/\/arocell.com\/sv\/","name":"IDL Diagnostics","description":"Saving lives with diagnostics","publisher":{"@id":"https:\/\/arocell.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/arocell.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/arocell.com\/sv\/#organization","name":"IDL Diagnostics","url":"https:\/\/arocell.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/arocell.com\/sv\/#\/schema\/logo\/image\/","url":"https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2022\/10\/AroCell_logo.png","contentUrl":"https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2022\/10\/AroCell_logo.png","width":1713,"height":570,"caption":"IDL Diagnostics"},"image":{"@id":"https:\/\/arocell.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/arocell","https:\/\/linkedin.com\/company\/arocell"]}]}},"_links":{"self":[{"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/pages\/2826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/comments?post=2826"}],"version-history":[{"count":1,"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/pages\/2826\/revisions"}],"predecessor-version":[{"id":5363,"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/pages\/2826\/revisions\/5363"}],"up":[{"embeddable":true,"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/pages\/2253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/media\/3954"}],"wp:attachment":[{"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/media?parent=2826"}],"wp:term":[{"taxonomy":"dipi_cpt_category","embeddable":true,"href":"https:\/\/idldiagnostics.com\/sv\/wp-json\/wp\/v2\/dipi_cpt_category?post=2826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}